Speaker
Description
Peking University has built a fully integrated ecosystem for radiopharmaceutical research that spans radionuclide production, drug discovery, and clinical translation, catalyzing innovation at the interface of nuclear science and precision medicine. At its core is the Radiopharmaceutical Research Center (Cyclotron Platform), anchored by the CIAE-developed CYCIAE-14 cyclotron (14.6-MeV protons), 68Ge/68Ga generators, and dedicated radiopharmaceutical synthesis laboratories.
These facilities support the production of a broad radionuclide portfolio—routine isotopes such as 18F and 68Ga as well as novel PET emitters including 64Cu, 86Y, and 89Zr. Peking University has also pioneered domestic production of key therapeutic and generator isotopes, notably 225Ac, 212Pb, and 213Bi, substantially reducing long-standing reliance on imports.
This radionuclide capability underpins extensive screening and preclinical evaluation of radiopharmaceuticals and BNCT agents at Peking University, accelerating the translation of candidates such as BF3-BPA and CTR-FAPI. Beyond clinical applications, isotopes—especially 89Zr and 64Cu—also enable a range of fundamental life-science studies across the university.
